Quadira Biosciences to use abc biopply’s 3D cell technology for antibody development

With its antibody screening platform, Xlife Sciences AG has already identified 30 compounds with blockbuster potential. These therapeutic antibodies have already been shown to be safe and effective in humans. Xlife can modify antibodies with pinpoint accuracy and increase the quality of the active components. These are mainly advanced, highly potent antibodies with higher cytotoxic activity and improved side effect profiles for cancer therapy. The targeted market potential of the pre-selected antibodies is in the range of several billion US dollars.

Xlife Sciences AG and Solothurn-based anfass Life Technologies AG have entered a joint venture. Hence, the jointly founded Quadira Biosciences AG has access to the 3D CoSeedis technology platform of abc biopply ag, a portfolio company of anfass Life Technologies.

The collaboration with abc biopply adds an important element to the development process. The 3D CoSeedis technology platform developed by abc biopply allows the testing and characterization of the efficacy of antibodies in 3D cell cultures, so-called organoids, that mimic animal or human tissue. This reduces or even eliminates animal testing and significantly accelerates product development. 3D CoSeedis is characterized by the unique homogeneity of the generated spheroids and enables their standardized mass production. Ultimately, this massively simplifies preclinical disease modeling. The partnership with Quadira Bioscience now creates a sustainable concept that could revolutionize cancer therapy.